NCT00160433View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.

PHASE2CompletedINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions

Endometriosis

Interventions

DRUG

Asoprisnil

0.5 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

1.5 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

5.0 mg Tablet, oral Daily for 12 weeks

DRUG

Placebo

Tablet, oral Daily for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Jenapharm GmbH & Co. KG

UNKNOWN

lead

Abbott

INDUSTRY